b cell prolymphocytic leukemia jvm 3 Search Results


cell lines b cel l prolymphocytic leukemia pll cell lines jvm 3  (DSMZ)
94
DSMZ cell lines b cel l prolymphocytic leukemia pll cell lines jvm 3
Cell Lines B Cel L Prolymphocytic Leukemia Pll Cell Lines Jvm 3, supplied by DSMZ, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/b+cell+prolymphocytic+leukemia+jvm+3/JVM-3/pmc04847985-251-0-18
Average 94 stars, based on 1 article reviews
cell lines b cel l prolymphocytic leukemia pll cell lines jvm 3 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier
jvm3  (DSMZ)
95
DSMZ jvm3
Jvm3, supplied by DSMZ, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/b+cell+prolymphocytic+leukemia+jvm+3/GRANTA-519/10__1158_slash_1078___0432__ccr___20___2149-56-3-11
Average 95 stars, based on 1 article reviews
jvm3 - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier
p53wild type  (DSMZ)
94
DSMZ p53wild type
Figure 2. Transcriptional downmodulation of TCL1 by Nutlin-3 in <t>p53wild-type</t> B-CLL cells. B-CLL leukemic patient samples (Table 1) and cell lines (EHEB, MEC1, MEC2, <t>JVM2,</t> <t>JVM3,</t> and BJAB) were either left untreated or exposed to Nutlin-3 (10 mmol/L). After 24 hours of treatment, mRNA levels of TCL1 and MDM2 (analyzed as the internal control, for comparison) were assessed by quantitative real-time PCR. Results were expressed as fold of either TCL1 (A) or MDM2 (B) modulation in Nutlin-3– treated cultures with respect to the control untreated cultures, which were set to 1 (white bars). TCL1 and MDM2 mRNA modulation was compared between the p53wild-type (p53wt) and the p53mutated (p53mut) leukemic patient cell samples or cell lines. In A and B, data are expressed as means SD. *, P < 0.05. In C, TCL1 and MDM2 protein modulation by Nutlin-3, analyzed by Western blot analysis, are shown for representative B-CLL patient (Pt.) samples and B-CLL cell lines after 24 hours of treatment. Tubulin staining is shown as the loading control.
P53wild Type, supplied by DSMZ, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/b+cell+prolymphocytic+leukemia+jvm+3/JVM-2/10__1158_slash_1078___0432__ccr___11___1064-42-1-19
Average 94 stars, based on 1 article reviews
p53wild type - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

Image Search Results


Figure 2. Transcriptional downmodulation of TCL1 by Nutlin-3 in p53wild-type B-CLL cells. B-CLL leukemic patient samples (Table 1) and cell lines (EHEB, MEC1, MEC2, JVM2, JVM3, and BJAB) were either left untreated or exposed to Nutlin-3 (10 mmol/L). After 24 hours of treatment, mRNA levels of TCL1 and MDM2 (analyzed as the internal control, for comparison) were assessed by quantitative real-time PCR. Results were expressed as fold of either TCL1 (A) or MDM2 (B) modulation in Nutlin-3– treated cultures with respect to the control untreated cultures, which were set to 1 (white bars). TCL1 and MDM2 mRNA modulation was compared between the p53wild-type (p53wt) and the p53mutated (p53mut) leukemic patient cell samples or cell lines. In A and B, data are expressed as means SD. *, P < 0.05. In C, TCL1 and MDM2 protein modulation by Nutlin-3, analyzed by Western blot analysis, are shown for representative B-CLL patient (Pt.) samples and B-CLL cell lines after 24 hours of treatment. Tubulin staining is shown as the loading control.

Journal: Clinical Cancer Research

Article Title: Nutlin-3 Downregulates the Expression of the Oncogene TCL1 in Primary B Chronic Lymphocytic Leukemic Cells

doi: 10.1158/1078-0432.ccr-11-1064

Figure Lengend Snippet: Figure 2. Transcriptional downmodulation of TCL1 by Nutlin-3 in p53wild-type B-CLL cells. B-CLL leukemic patient samples (Table 1) and cell lines (EHEB, MEC1, MEC2, JVM2, JVM3, and BJAB) were either left untreated or exposed to Nutlin-3 (10 mmol/L). After 24 hours of treatment, mRNA levels of TCL1 and MDM2 (analyzed as the internal control, for comparison) were assessed by quantitative real-time PCR. Results were expressed as fold of either TCL1 (A) or MDM2 (B) modulation in Nutlin-3– treated cultures with respect to the control untreated cultures, which were set to 1 (white bars). TCL1 and MDM2 mRNA modulation was compared between the p53wild-type (p53wt) and the p53mutated (p53mut) leukemic patient cell samples or cell lines. In A and B, data are expressed as means SD. *, P < 0.05. In C, TCL1 and MDM2 protein modulation by Nutlin-3, analyzed by Western blot analysis, are shown for representative B-CLL patient (Pt.) samples and B-CLL cell lines after 24 hours of treatment. Tubulin staining is shown as the loading control.

Article Snippet: The p53wild-type (EHEB, JVM2, and JVM3) and p53deleted/mutated (MEC1, MEC2, and BJAB) B leukemic cell lines were purchased from DSMZ (Deutsche Sammlung vonMikroorganismen und Zellkulturen GmbH) and cultured as described in Supplementary Methods.

Techniques: Control, Comparison, Real-time Polymerase Chain Reaction, Western Blot, Staining